U.S. markets open in 6 hours 2 minutes

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9400-0.0100 (-0.20%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close4.9500
Open4.9900
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range4.8400 - 5.0000
52 Week Range2.5000 - 6.0000
Volume114,899
Avg. Volume347,184
Market Cap304.425M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-0.4310
Earnings DateAug 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
    Business Wire

    New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice

    ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of nicotinamide riboside (NR) on maintaining telomeres, the protective regions at the end of DNA strands. This study is the first to show that by increasing NAD+, NR helped protect telomeres which are important in addressing life-threatening telomere-related diseases, paving the way for future clinical research. The study was conducted by investigators at the National Institute on Aging (NIA) and the National Cancer Institute (NCI), parts of the National Institutes of Health (NIH). The role of ChromaDex in this study was to provide NR through the ChromaDex External Research Program (CERP). All other aspects of the study, including analysis of the results and writing of the manuscript were conducted independently by the authors.

  • Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US
    Business Wire

    Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US

    ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Cellular Energy, a protein-based flavored drink mix to help renew natural processes that decline as we age. The new product includes a 250mg serving of Tru Niagen® (nicotinamide riboside, or NR) and is one of three products under the new Celltrient brand.

  • New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function
    Business Wire

    New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function

    ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice. In a preclinical mouse model, NR was shown to improve T-cell function, which is a component of new cancer immunotherapies such as PD-1 and PDL-1 inhibitors. These findings lend further data to the potential role of NR in supporting healthy mitochondrial function.